PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Increasing Demand for Active Lifestyles & Non-surgical Treatment Options Drive European Osteoarthritis Market - New analysis from Frost & Sullivan, European Osteoarthritis Market, reveals that this market earned revenues of $121.2 million in 2006 and estimates this to reach $139.7 million in 2013
Increasing Demand for Active Lifestyles & Non-surgical Treatment Options Drive European Osteoarthritis Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/07/10 - New analysis from Frost & Sullivan, European Osteoarthritis Market, reveals that this market earned revenues of $121.2 million in 2006 and estimates this to reach $139.7 million in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

An increasing demand for active lifestyles as patients refuse to be disabled by osteoarthritis is one of the primary drivers of the European osteoarthritis market. Patients are seeking pharmacological treatment options rather than undergo surgical procedures, and this is promoting the demand for osteoarthritis drugs in Europe, where around 35 to 40 million of the population suffer from this disease in varying degrees of severity.

New analysis from Frost & Sullivan (pharmaceuticals.frost.com), European Osteoarthritis Market, reveals that this market earned revenues of $121.2 million in 2006 and estimates this to reach $139.7 million in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of European Osteoarthritis Market, then send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore@[.]frost.com with your full name, company name, title, telephone number, fax number and email address. Upon receipt of the above information, an overview will be sent to you by email.

“It must be kept in mind, however, that there are no actual curative therapies available for osteoarthritis,” notes Frost & Sullivan Industry Analyst Ms. Sylvia Miriyam Findlay. “The focus of osteoarthritis management is rather on reducing pain, inflammation and disability by retarding cartilage damage and increasing joint function.”

Non-steroidal anti-inflammatory drugs (NSAIDs) are the class of medications most commonly used to treat mild to moderate arthritic pain. Traditional NSAIDs are non-selective and act by blocking both cyclooxygenase (COX) 1 and 2 that are involved in prostaglandin production.

However, some of these NSAIDs, even the highest-selling ones, were withdrawn from the market due to significant doubts over their side effects and safety profile. Due to these controversies, the physician and patient community is now looking to newer treatment options such as hyaluronic acid (HA) or steroidal injections for pain relief.

The HA market has been gaining popularity in Europe and is poised to penetrate the European osteoarthritis market further, but this is likely to occur only if sufficient clinical trials substantiate the efficacy of this therapy. The HA market is still untapped and is likely to attract many more participants, while its low entry barriers could encourage the introduction of newer HA products.

Proper diagnosis of the disease is still a major unmet need in the industry, as there are no effective biomarkers or diagnostic tests available to diagnose or monitor the progression of the disease. There also exists a real need for the introduction of disease-modifying drugs with an improved safety profile.

Currently, there is a huge gap in treatment options if patients do not respond to the current pain-relieving therapies and are not ready for joint replacement. These are the critical restraints for the European osteoarthritis market.

“Companies are pursuing stem cell therapies to address this need as these are not only non-invasive but also lead to tissue regeneration,” says Ms. Findlay. “Such therapies are likely to enhance the growth of the European osteoarthritis market.”

European Osteoarthritis Market, part of the Pharmaceutical and Biotechnology Growth Partnership Service programme, provides an overview of the current treatment options along with a complete analysis of key market drivers, restraints and trends prevailing in the market. It also provides a detailed analysis of the hyaluronic acid market, its revenues and technological advancements. Interviews with the press are available.

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Increasing Demand for Active Lifestyles & Non-surgical Treatment Options Drive European Osteoarthritis Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Radhika Menon Theodore 
+91 44 42044541 rmtheodore@[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)